Press release – For immediate release – 5:45 pm CEST
H2 2025 Financial Communication Calendar
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announces today its H2 2025 financial communication calendar.
| Publication | Date |
| H1 2025 results | October 23, 2025, release after market close |
The Company will participate in upcoming investor events:
European MidCap Event 2025 – September 30 – October 1st, 2025 – Paris, France
Portzamparc Biotech and Healthcare Sector Investor Seminar – October 1-2, 2025 (digital)
Investor Access Conference 2025 – October 7-8, 2025 – Paris, France
Please get in touch through the respective event booking systems, if you would like to request a meeting with Median management at these events. Events are for institutional investors only.
Pioneering innovative imaging services and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit